

Yoshihiko Tomita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5968214/publications.pdf>

Version: 2024-02-01

71
papers

12,621
citations

257450

24
h-index

118850

62
g-index

75
all docs

75
docs citations

75
times ranked

13045
citing authors

#	ARTICLE	IF	CITATIONS
1	Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 383-395.	2.2	8
2	Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. <i>ESMO Open</i> , 2022, 7, 100450.	4.5	14
3	A Novel Method of CD31-Combined ABO Carbohydrate Antigen Microarray Predicts Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation. <i>Transplant International</i> , 2022, 35, 10248.	1.6	3
4	Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 966-975.	1.3	12
5	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	27.0	961
6	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 2102-2114.	27.0	427
7	Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1656-1664.	1.3	7
8	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	7.0	25
9	Significance of PSA Screening in Niigata, Japan: Survey of Actual Status of New Cases of Prostate Cancer. <i>Research and Reports in Urology</i> , 2021, Volume 13, 859-866.	1.0	0
10	Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 12-19.	1.3	39
11	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
12	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020, 5, e001079.	4.5	343
13	Cabozantinib in advanced renal cell carcinoma: A phase III, open-label, single-arm study of Japanese patients. <i>International Journal of Urology</i> , 2020, 27, 952-959.	1.0	17
14	Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture: overlapped pathological features among papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, and unclassified RCC. <i>Lessons from a Japanese multicenter study. Japanese Journal of Clinical Oncology</i> , 2020, 50, 1313-1320.	1.3	1
15	Perioperative therapies for urological cancers. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 357-367.	1.3	3
16	Intraoperative intraocular pressure changes during robot-assisted radical prostatectomy: associations with perioperative and clinicopathological factors. <i>BMC Urology</i> , 2020, 20, 26.	1.4	4
17	Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. <i>Cancer Science</i> , 2020, 111, 907-923.	3.9	33
18	Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e374-e385.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Clinically relevant GSK-3 β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer. <i>International Journal of Molecular Medicine</i> , 2020, 45, 315-323.	4.0	12
20	Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment. <i>Oncology Letters</i> , 2020, 21, 64.	1.8	10
21	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	10.7	594
22	Bortezomib Eliminates Plasma Cells From a Renal Graft in Plasma Cell-Rich Acute Rejection. <i>Transplantation Proceedings</i> , 2019, 51, 1732-1738.	0.6	9
23	Unicentric Castleman's disease located between the aorta and inferior vena cava: A case report. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1983953.	0.3	0
24	Limited significance of repeated long-term radiological and hormonal examination in nonfunctioning adrenal incidentalomas. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 503-513.	1.5	3
25	Analysis of the prevalence of systemic de novo thrombotic microangiopathy after ABO-incompatible kidney transplantation and the associated risk factors. <i>International Journal of Urology</i> , 2019, 26, 1128-1137.	1.0	19
26	Solitary brain metastasis from prostate cancer after multi modality treatment: A case report. <i>Urology Case Reports</i> , 2019, 24, 100879.	0.3	6
27	Retrospective Analysis to Determine the Optimal Timing to Discontinue Continuous Antibiotic Prophylaxis in Patients with Primary Vesicoureteral Reflux. <i>Urologia Internationalis</i> , 2019, 102, 462-467.	1.3	4
28	Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 506-514.	1.3	41
29	9-ING-41, a small molecule inhibitor of GSK-3 β , potentiates the effects of anticancer therapeutics in bladder cancer. <i>Scientific Reports</i> , 2019, 9, 19977.	3.3	32
30	Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. <i>BMC Cancer</i> , 2019, 19, 17.	2.6	4
31	Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. <i>International Journal of Urology</i> , 2019, 26, 202-210.	1.0	27
32	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 451-460.	10.7	228
33	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	27.0	3,334
34	Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1201-e1214.	1.9	5
35	Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 639-646.	1.3	51
36	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017, 72, 368-376.	1.9	209

#	ARTICLE	IF	CITATIONS
37	Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. <i>Cancer Science</i> , 2017, 108, 1231-1239.	3.9	21
38	Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen. <i>BMC Cancer</i> , 2016, 16, 332.	2.6	3
39	Clinicopathological features and outcomes in patients with late recurrence of renal cell carcinoma after radical surgery. <i>International Journal of Urology</i> , 2016, 23, 132-137.	1.0	5
40	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 499-503.	1.9	39
41	Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1031-1041.	1.3	20
42	Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes. <i>International Journal of Urology</i> , 2016, 23, 153-158.	1.0	25
43	A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression. <i>BMC Cancer</i> , 2016, 16, 805.	2.6	9
44	Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: single institution experience and outcomes. <i>Journal of Radiation Research</i> , 2016, 57, 280-287.	1.6	10
45	Sequential molecularly targeted drug therapy including axitinib for a patient with end-stage renal failure and metastatic renal cell carcinoma. <i>Hemodialysis International</i> , 2016, 20, E1-4.	0.9	10
46	Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment. <i>International Journal of Urology</i> , 2016, 23, 13-21.	1.0	12
47	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	27.0	4,889
48	Suspicion of primary testicular germ cell tumor regressed completely before metastasis. <i>International Cancer Conference Journal</i> , 2014, 3, 87-90.	0.5	0
49	Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients. <i>Urology</i> , 2013, 82, 846-851.	1.0	61
50	Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 616-628.	1.3	68
51	Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients. <i>European Urology</i> , 2010, 57, 317-326.	1.9	180
52	Glycogen Synthase Kinase-3 β : A Prognostic Marker and a Potential Therapeutic Target in Human Bladder Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5124-5132.	7.0	76
53	Metastatic Renal Cell Carcinoma: Use of Bcl-2 and Fas to Predict Responses to Immunotherapy. , 2010, , 137-145.		0
54	Early renal cell cancer. <i>International Journal of Clinical Oncology</i> , 2006, 11, 22-27.	2.2	11

#	ARTICLE	IF	CITATIONS
55	Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. <i>International Journal of Cancer</i> , 2003, 103, 29-37.	5.1	114
56	Role of IRF-1 and caspase-7 in IFN- γ enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. <i>International Journal of Cancer</i> , 2003, 104, 400-408.	5.1	52
57	G-protein coupled receptor kinase 2 and 3 expression in human detrusor cultured smooth muscle cells. <i>Urological Research</i> , 2001, 29, 325-329.	1.5	3
58	The prevalence of renal cell carcinoma: A nation-wide survey in Japan in 1997. <i>International Journal of Urology</i> , 2001, 8, 359-365.	1.0	27
59	Application of Antisense Technology to Urologic Cancers. <i>Molecular Urology</i> , 2000, 4, 55-59.	1.0	0
60	Use of Miniature Ultrasonic Probe System for Intravesical Ultrasonography for Transitional Cell Cancer of the Urinary Tract. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 313-316.	1.4	7
61	Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and Adriamycin on transitional cell cancer cells. <i>Cancer Letters</i> , 2000, 155, 191-198.	7.2	35
62	Pharmacological and molecular biological evidence for ETA endothelin receptor subtype mediating mechanical responses in the detrusor smooth muscle of the human urinary bladder. <i>Clinical Science</i> , 1999, 96, 397-402.	4.3	15
63	Variable Bcl-2 phenotype in benign and malignant lesions of urothelium. <i>Cancer Letters</i> , 1998, 128, 87-92.	7.2	17
64	Treatment of Bilateral Renal Cell Cancer and Multiple Lung Metastasis: Nephron-Sparing Surgery and Resection of Lung Tumors after Interleukin-2 Therapy. <i>European Urology</i> , 1998, 33, 238-240.	1.9	3
65	Alpha-1 adrenoceptor subtypes (high, low) in human benign prostatic hypertrophy tissue according to the affinities for prazosin. , 1997, 31, 216-222.		10
66	Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. , 1996, 66, 322-325.		62
67	Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1 (CD95)-mediated apoptosis in renal-cell-cancer cells. , 1996, 68, 132-135.		24
68	Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. , 1996, 68, 501-505.		46
69	Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. <i>International Journal of Cancer</i> , 1996, 68, 501-505.	5.1	1
70	Interferon β but not tumor necrosis factor α decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells. <i>Cancer Immunology, Immunotherapy</i> , 1992, 35, 381-387.	4.2	20
71	Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: Possible significance in host immune responses. <i>International Journal of Cancer</i> , 1990, 46, 1001-1006.	5.1	86